Trial Profile

Efficacy of Rafiximin in Patients With Cirrhotic Gastroesophageal Variceal Hemorrhage: A Single-center Pilot Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifaximin (Primary)
Indications Gastrointestinal haemorrhage; Oesophageal varices; Variceal haemorrhage
Focus Adverse reactions
Acronyms RFXM

Most Recent Events

04 May 2018 Status changed from recruiting to completed.
16 Aug 2017 Planned number of patients changed from 50 to 60.
16 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com